Gossamer Bio (NASDAQ:GOSS) Receives Outperform Rating from Wedbush

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a report issued on Friday,Benzinga reports. They currently have a $4.00 price objective on the stock. Wedbush’s price objective indicates a potential upside of 201.89% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a report on Thursday, January 30th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Gossamer Bio presently has a consensus rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Stock Up 1.9 %

Shares of NASDAQ:GOSS traded up $0.03 during trading on Friday, hitting $1.33. 210,068 shares of the company were exchanged, compared to its average volume of 1,545,757. Gossamer Bio has a 12-month low of $0.50 and a 12-month high of $1.55. The stock has a market capitalization of $300.25 million, a P/E ratio of -4.14 and a beta of 1.86. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The firm’s 50 day moving average price is $1.12 and its 200-day moving average price is $0.96.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). On average, research analysts predict that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Octagon Capital Advisors LP boosted its stake in Gossamer Bio by 99.7% during the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after purchasing an additional 9,162,117 shares during the period. Alyeska Investment Group L.P. boosted its holdings in Gossamer Bio by 52.7% in the 4th quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock valued at $7,968,000 after purchasing an additional 3,041,058 shares during the period. Monaco Asset Management SAM grew its position in Gossamer Bio by 39.5% in the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after purchasing an additional 1,520,721 shares during the last quarter. Allostery Investments LP bought a new position in shares of Gossamer Bio during the 4th quarter worth about $555,000. Finally, Silverarc Capital Management LLC raised its position in shares of Gossamer Bio by 9.3% during the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock valued at $5,583,000 after buying an additional 526,495 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.